Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: We evaluated the concordance/discordance of PD-L1 staining results between the 28-8 and 22C3 assays and its impact on the efficacy outcomes of advanced gastric cancer patients treated with nivolumab plus chemotherapy.
Methods: This retrospective study involved 143 gastric cancer patients treated with first-line nivolumab plus chemotherapy whose PD-L1 results with both 28-8 and 22C3 assays were available. The concordance/discordance between these assays and the inter-observer variability were evaluated for PD-L1 combined positive score (CPS) positivity. Discordant PD-L1 results were analyzed regarding survival outcomes.
Results: The agreement rates and Cohen's kappa values between the 28-8 and 22C3 assays were 78.3% and 0.56 (for CPS ≥ 1), 81.8% and 0.60 (for CPS ≥ 5), and 88.8% and 0.66 (for CPS ≥ 10), respectively. Inter-observer variability, as represented by the intra-class correlation coefficient, was 0.89 and 0.88 for the 28-8 and 22C3 assays, respectively. With PD-L1 CPS ≥ 5 defined as positive, 35 (24.5%) and 82 (57.3%) had concordantly positive and negative results, respectively, between the 28-8 and 22C3 assays, whereas 26 (18.2%) had discordant results. Progression-free survival was shorter for those who exhibited negatively concordant PD-L1 results and discordant PD-L1 positivity between the 28-8 and 22C3 assays relative to those with positively concordant PD-L1 results (P = 0.013).
Conclusion: PD-L1 assays by 28-8 and 22C3 showed suboptimal concordance, while inter-observer variability was not critical in advanced gastric cancer. Discordant PD-L1 results between 28-8 and 22C3 assays may be associated with unfavorable efficacy outcomes in patients treated with nivolumab plus chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10120-024-01500-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma.
Sci Rep
July 2025
Department of Urology, Fukushima Medical University School of Medicine, 1, Hikarigaoka, Fukushima, 960-1295, Japan.
Therapeutic strategies for advanced renal cell carcinoma have advanced dramatically since the approval of immune checkpoint inhibitors. To date, four PD-L1 assays have been established as companion diagnostic tools for checkpoint inhibitors. However, all PD-L1 assays present several limitations in terms of concordance and compatibility.
View Article and Find Full Text PDFMyomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients.
J Transl Med
June 2025
Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, Vestec, 252 50, Czech Republic.
Background: The treatment of non-small cell lung cancer (NSCLC) patients is correlated with the efficacy of immune checkpoint blockade therapy (ICB) targeting programmed cell death ligand 1 (PD-L1) or its cognate receptor (PD-1) on cancer cells or infiltrating immune cells. Analysis of PD-L1/PD-1 expression in tumor tissue represents a crucial step before PD-L1/PD-1 blocker usage.
Methods: We used directed evolution of protein variants derived from a 13 kDa Myomedin loop-type combinatorial library with 12 randomized amino acid residues to select high-affinity binders of human PD-L1 (hPD-L1).
Programmed Death-Ligand 1 Expression Across Multiple Assays in Ovarian Cancer: A Comparative Analysis.
Cancer Res Treat
June 2025
Department of Pathology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
Purpose: Ovarian cancer presents significant treatment challenges due to its aggressive nature and poor response to immune checkpoint inhibitors (ICIs). The lack of standardized programmed cell death-ligand 1 (PD-L1) assays and cut-off values complicates clinical decision-making. We evaluated the concordance among commonly used PD-L1 assays and assessed changes in the expression of PD-L1 following chemotherapy.
View Article and Find Full Text PDFComparison of PD-L1 assays in head and neck carcinoma.
Pathology
December 2024
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address:
Article Synopsis
- PD-L1 expression serves as a crucial biomarker in predicting how patients with head and neck squamous cell carcinoma might respond to immune checkpoint inhibitors, making it important to evaluate different testing methods.
- A study conducted at Asan Medical Center evaluated PD-L1 expression in 156 cases using various standardized assays and a laboratory-developed test, revealing good to excellent agreement among the methods.
- The results highlighted that PD-L1 expression significantly varies with tumor location and suggests that the different assays could potentially be used interchangeably for assessing PD-L1 in head and neck cancers.
Programmed death-ligand 1 expression in carcinoma of unknown primary.
BMC Cancer
June 2024
Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
Article Synopsis
- - The study focused on the expression of PD-L1 in carcinoma of unknown primary (CUP) by analyzing tissue samples from 72 cases, using various immunohistochemical methods.
- - The PD-L1 positivity rates in CUP varied significantly depending on the antibodies used, with rates ranging from 5.6% to 48.6%, but these rates did not change with different histologic or clinical subtypes.
- - Analysis showed that while PD-L1 expression was inconsistent across various scoring systems, there was a fair level of agreement between different antibodies used in the study.